Futura Medical (LSE:FUM), the AIM-quoted developer of the Eroxon erectile dysfunction gel, is in focus on the FTSE AIM All Share index after reporting positive results on 7 October 2026 from a further home user test of its new Eroxon Intense formula, at a time when the company is in a formal sale process under the Takeover Code.
The latest study involved 115 men aged 18 to 59, most with mild to moderate erectile dysfunction. Futura said satisfaction with erection hardness was reported in 82% of encounters, compared with 71% for the original Intense formula, and that the improvement in a standard erectile function score exceeded the clinically meaningful threshold. The new formula is planned for commercialisation in the first half of 2027, and the company said Brand positioning work was nearing completion.
What the Company Does
Futura Medical develops consumer healthcare products for sexual health. Its lead product, Eroxon, is described by the company as the only over-the-counter topical gel for erectile dysfunction and is sold through licence and distribution partners in several major markets. The pipeline includes Eroxon Intense and WSD4000, a gel being developed for female sexual health.
Fundraise and Formal Sale Process
On 3 September 2026, Futura announced a fundraise at 0.2p per share alongside the launch of a formal sale process and a wider M&A process covering asset sales, licensing or other arrangements. Including an oversubscribed retail offer that was upscaled to £200,000, the company said it had conditionally raised about £1.8m before expenses. Shareholders approved the required resolutions at a general meeting on 23 September, after which total voting rights stood at 1,482,327,755 shares.
The issue price represented a discount of about 37.6% to the previous closing price. The company said the proceeds would extend its cash runway into February 2027 and fund product development and the sale process. Advisers were appointed to run the processes, with non-binding offers requested by 2 October 2026. At launch, Futura stated that it was not in talks with, and had not received an approach from, any potential offeror, and it cautioned that possible outcomes without the fundraise could have included an orderly wind-down. No result from the process had been announced at the time of writing.
Commercial Picture
Eroxon sales have been slower than expected, though the company said in-market sales had begun to stabilise over the four quarters to June 2026. Its relationship with Haleon ended in June, and Market Performance Group became its US commercial partner from 1 September. Futura has also received EU clearance for Eroxon Intense and expects US FDA clearance in the fourth quarter of 2026. The board believes the market valuation does not reflect the portfolio's potential, and estimates that a pivotal WSD4000 study would require around £4m of further investment. No Dividend is paid.
Sector and Index Context
Consumer health innovators often depend on large partners for distribution, and slow uptake can strain a small company's finances. Futura is one of the smaller healthcare names on the FTSE AIM All Share Index, where funding and corporate activity can drive sharp share price moves.
Key Risks
Key risks include the limited cash runway, the possibility that the sale process does not produce an acceptable offer, regulatory timing for Eroxon Intense, and the substantial dilution already seen from the latest fundraise, with new shares representing around 60% of the enlarged share capital. Non-executive director Roy Davis is also due to step down on 20 October 2026.
What to Watch Next
Investors will look for updates on the formal sale process following the non-binding offer deadline, FDA clearance for Eroxon Intense, progress with partners in China and other markets, and any funding route for WSD4000.






Please wait processing your request...